TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07592585: Phase III Clinical Study to Evaluate the Efficacy and Safety of VC005 in Adult and Adolescents With Mild to Moderate Atopic Dermatitis

Sponsor: Jiangsu vcare pharmaceutical technology co., LTD · Phase: PHASE3 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 360 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$11,723,520

Rescue Site Savings

+$7,730,196

Unlock Full NCT07592585 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07592585 Rescue Dossier →